Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

Morningstar brands and products Company Portfolio ...

04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...